Sign in to view content

Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration

Keyvan Koushan, MD, FRCSC

Video
Published 2023

Related

High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Annual Meeting Talks
2020
An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2023
Fluctuations in Central Foveal Thickness and Vision Outcomes With Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more